Market Overview

Needham: Stryker Deal Not Dead For Smith & Nephew

Related SYK
Brean Digs Into Osiris Therapeutics 10Q, Downgrades To Sell
Earnings Scheduled For October 22, 2015

Smith & Nephew's (NYSE: SNN) chief executive says he's not interested, but Stryker (NYSE: SYK) still might prevail with a bid, one analyst said Tuesday.

Needham's Michael Matson said such a deal is "highly probable" and would boost Stryker's earnings 12 percent within a year even apart from tax inversion benefits. Matson upgraded Stryker from Hold to Buy, setting a $93 target in a note Tuesday.

Stryker Chief Executive Ken Lobos said in May that the company was considering a bid for Smith & Nephew, but then backed off and said no offer was coming.

British securities law bars Lobos from making an unsolicited offer for six months following the statement, unless a rival bidder materializes. Smith & Nephew's CEO Olivier Bohuon said he's not interested.

“A good deal must always have a strategy component. If it's just for money, I'm not sure this is great,” Bohuon told the U.K's Telegraph in June.

Any U.S. company that acquired U.K.-based Stryker would have the opportunity for a so-called tax inversion, avoiding relatively high U.S. corporate taxes by moving its headquarters offshore.

Acquiring Smith & Nephew would instantly make Stryker number two in reconstructive sales, number one in sports medicine, significantly boost its number two position in trauma, according to Matson, who figured Smith & Nephew holders would get a 20 percent premium.

Smith closed up 1.5 percent; Stryker closed up 0.05 percent.

Latest Ratings for SYK

Nov 2015Goldman SachsDowngradesBuyNeutral
Nov 2015CitigroupInitiates Coverage onSell
Nov 2015Sterne Agee CRTInitiates Coverage onNeutral

View More Analyst Ratings for SYK
View the Latest Analyst Ratings

Posted-In: Michael Matson NeedhamAnalyst Color News M&A Analyst Ratings


Related Articles (SNN + SYK)

Get Benzinga's Newsletters